[go: up one dir, main page]

ECSP23058279A - Antagonistas de gitr y métodos de uso de los mismos - Google Patents

Antagonistas de gitr y métodos de uso de los mismos

Info

Publication number
ECSP23058279A
ECSP23058279A ECSENADI202358279A ECDI202358279A ECSP23058279A EC SP23058279 A ECSP23058279 A EC SP23058279A EC SENADI202358279 A ECSENADI202358279 A EC SENADI202358279A EC DI202358279 A ECDI202358279 A EC DI202358279A EC SP23058279 A ECSP23058279 A EC SP23058279A
Authority
EC
Ecuador
Prior art keywords
methods
compounds
gitr antagonists
gitr
antagonists
Prior art date
Application number
ECSENADI202358279A
Other languages
English (en)
Inventor
Mark Andrew Wortinger
Paul Francis Cain
Stacey Lynn Lee
Melinda Ann Lacerte
Petra Verdino
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP23058279A publication Critical patent/ECSP23058279A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción se refiere a compuestos que se unen al GITR humano, composiciones farmacéuticas que comprenden tales compuestos y métodos de uso de tales compuestos.
ECSENADI202358279A 2021-02-02 2023-08-01 Antagonistas de gitr y métodos de uso de los mismos ECSP23058279A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163144732P 2021-02-02 2021-02-02
US202263297968P 2022-01-10 2022-01-10

Publications (1)

Publication Number Publication Date
ECSP23058279A true ECSP23058279A (es) 2023-09-29

Family

ID=80787518

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202358279A ECSP23058279A (es) 2021-02-02 2023-08-01 Antagonistas de gitr y métodos de uso de los mismos

Country Status (16)

Country Link
US (2) US11859005B2 (es)
EP (1) EP4288097A1 (es)
JP (1) JP7728873B2 (es)
KR (1) KR102856892B1 (es)
AU (1) AU2022216230A1 (es)
CA (1) CA3205852A1 (es)
CL (1) CL2023002288A1 (es)
CO (1) CO2023009885A2 (es)
CR (1) CR20230365A (es)
DO (1) DOP2023000143A (es)
EC (1) ECSP23058279A (es)
IL (1) IL304434A (es)
MX (1) MX2023009007A (es)
PE (1) PE20240914A1 (es)
TW (1) TW202246334A (es)
WO (1) WO2022169766A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025085352A1 (en) 2023-10-18 2025-04-24 Eli Lilly And Company Transferrin receptor binding proteins and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
MX2012009460A (es) * 2010-03-03 2012-09-12 Boehringer Ingelheim Int Polipeptidos biparatopicos de union abeta.
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
NZ627260A (en) * 2012-02-27 2015-10-30 Boehringer Ingelheim Int Cx3cr1-binding polypeptides
KR101549637B1 (ko) 2012-06-08 2015-09-03 국립암센터 신규한 Ｔｈ1 세포 전환용 에피토프 및 이의 용도
MX377844B (es) 2014-05-28 2025-03-11 Agenus Inc Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso.
JP7628764B2 (ja) * 2015-09-29 2025-02-12 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
WO2017096276A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
AU2016364895A1 (en) 2015-12-02 2018-06-07 Agenus Inc. Anti-GITR antibodies and methods of use thereof
CA3016894A1 (en) * 2016-03-08 2017-09-14 Janssen Biotech, Inc. Gitr antibodies, methods, and uses
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
WO2018138521A1 (en) * 2017-01-27 2018-08-02 Ultrahuman One Limited Binding agents
RU2019127550A (ru) * 2017-03-03 2021-04-05 Ринат Ньюросайенс Корп. Анти-gitr антитела и способы их использования
CN110520436A (zh) 2017-03-15 2019-11-29 潘迪恩治疗公司 靶向免疫耐受性
AU2018241535A1 (en) * 2017-03-31 2019-11-07 Zymeworks Inc. Tumor antigen presentation inducer constructs and uses thereof

Also Published As

Publication number Publication date
CO2023009885A2 (es) 2023-08-09
JP7728873B2 (ja) 2025-08-25
WO2022169766A1 (en) 2022-08-11
IL304434A (en) 2023-09-01
MX2023009007A (es) 2023-08-08
AU2022216230A9 (en) 2024-10-10
PE20240914A1 (es) 2024-04-30
KR20230122171A (ko) 2023-08-22
AU2022216230A1 (en) 2023-07-20
KR102856892B1 (ko) 2025-09-10
US20220251227A1 (en) 2022-08-11
US11859005B2 (en) 2024-01-02
JP2024505563A (ja) 2024-02-06
EP4288097A1 (en) 2023-12-13
CA3205852A1 (en) 2022-08-11
TW202246334A (zh) 2022-12-01
US20240158525A1 (en) 2024-05-16
CR20230365A (es) 2023-09-08
DOP2023000143A (es) 2023-09-15
CL2023002288A1 (es) 2024-02-02

Similar Documents

Publication Publication Date Title
CL2022000447A1 (es) Inhibidores de kras g12d
CO2020007244A2 (es) Inhibidores de kras g12c
ECSP22012826A (es) Inhibidores de parp1
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
UY39296A (es) Azaquinolonas sustituidas inhibidoras de parp y composiciones farmacéuticas que las contienen
CL2019000793A1 (es) Moduladores de calpaínas y usos terapéuticos de los mismos.
CU20220005A7 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
BR112018006259A2 (pt) "adjunto compressível com estruturas de suporte intermediárias"
CO2017012995A2 (es) Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
MX2020009275A (es) Composiciones de anticuerpo anti-pd-1.
MX2021006977A (es) Anellosomas y metodos de uso.
CL2020002680A1 (es) Anticuerpos para radionúclidos quelados
CL2008001835A1 (es) Uso de compuestos derivados de guaninas policiclicas para tratar la inflamacion; compuestos derivados de guanina; y compocicion farmaceutica que los comprende.
CL2021003228A1 (es) Compuestos tricíclicos y su uso
CO2022009510A2 (es) Compuestos activos frente a receptores nucleares
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
CO2024000890A2 (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
DOP2020000104A (es) Métodos de uso y composiciones que contienen dulaglutida
CO2024000763A2 (es) Composiciones y métodos de los anticuerpos anti-pacap
ECSP23058279A (es) Antagonistas de gitr y métodos de uso de los mismos
CL2019002629A1 (es) Análogos de deutetrabenazina, su preparación y uso.
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico